Eyepoint, Inc. · NASDAQ:EYPT
Eyepoint — EyePoint Pharmaceuticals — Investor Presentation (October 2025)
27 slides from Eyepoint's investor presentation, Oct 14, 2025
Slide 1: Investor Presentation October 2025
Investor Presentation October 2025 Exhibit 99.2
Slide 2: Legal Disclaimers
Legal Disclaimers Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, even
Slide 3: A Leader in Sustained Release Drug Delivery for Retinal Disease
A Leader in Sustained Release Drug Delivery for Retinal Disease 1. Unaudited estimate for September 30, 2025. Our actual results as of September 30, 2025, may differ from the preliminary financial data due to the completion of our closing procedures with respect to the fiscal quarter ended September
Slide 4: Pipeline Pursuing Large Market Opportunities
Pipeline Pursuing Large Market Opportunities wet AMD, wet age-related macular degeneration; DME, diabetic macular edema; FPI, first patient in; PK, pharmacokinetics Durasert E™ Programs Indication Discovery Pre-Clin Phase 1 Phase 2 Phase 3 Anticipated Milestone DURAVYU™ (vorolanib intravitreal inser
Slide 5: Wet AMD And DME Represent >80% of the Total Branded Market
Source: Internal estimates based on publicly reported actual and estimated sales data. wet AMD, wet age-related macular degeneration; DME, diabetic macular edema; NPDR, non-proliferative diabetic retinopathy, RVO, retinal vein occlusion Wet AMD And DME Represent >80% of the Total Branded Market DURA
Slide 6: Durasert E: The Next Generation in Sustained-Release Intravitreal Drug Delivery
Durasert E™: The Next Generation in Sustained-Release Intravitreal Drug Delivery Insert not drawn to scale, for illustrative purposes only. a Vitrasert now discontinued. b Data from preclinical studies. Following a single DURAVYU 900 µg dose in Dutch-Belted rabbits, vorolanib reached concentrations
Slide 7: Data Suggests Robust Efficacy Outcomes and a Strong Safety Profile Across Multiple Indications
DURAVYU Data Suggests Robust Efficacy Outcomes and a Strong Safety Profile Across Multiple Indications AMD, age-related macular degeneration; DME, diabetic macular edema; NPDR, non-proliferative diabetic retinopathy; OCT, optical coherence tomography. ClinicalTrials.gov identifiers: DAVIO NCT0474719
Slide 8: DURAVYU for Wet AMD
DURAVYU for Wet AMD Fully enrolled Phase 3 pivotal program on track to be first sustained-release TKI to market
Slide 9: LUGANO and LUCIA: Identical Phase 3 Pivotal Trials
DURAVYU in Wet AMD: LUGANO and LUCIA: Identical Phase 3 Pivotal Trials Evaluating Non-inferiority vs On-label Aflibercept & Based on interim masked safety data, the observed safety profile is consistent with previous DURAVYU clinical trials1 Both trials fully enrolled Topline 56-week data expected f
Slide 10: Phase 3 Pivotal Trial Design Following an Established Non-Inferiority Regulatory Pathway
DURAVYU in Wet AMD: Phase 3 Pivotal Trial Design Following an Established Non-Inferiority Regulatory Pathway DURAVYU dosing consists of 2 inserts delivered in a single injection. AMD, age-related macular degeneration; BCVA, best-corrected visual acuity; CST, central subfield thickness; D, day; EOS,
Slide 11: Commercial Manufacturing Facility to Support DURAVYU through Potential NDA Approval and Commercial Launch
Commercial Manufacturing Facility to Support DURAVYU through Potential NDA Approval and Commercial Launch cGMP, current good manufacturing practices; FDA, Federal Drug Administration; EMA, European Medicines Agency; cGMP, current good manufacturing practice USA based in Northbridge, MA Built to US F
Slide 12: DURAVYU for DME
DURAVYU for DME Phase 3 DME program plan underway Supported by Multi-MOA inhibition of both VEGF and IL-6
Slide 13: Diabetic Macular Edema: Large Market Opportunity with Significant Unmet Need
Diabetic Macular Edema: Large Market Opportunity with Significant Unmet Need for More Durable Treatments 1. William R. Rowley, Clement Bezold, Yasemin Arikan, et al. Diabetes 2030: Insights from Yesterday, Today and Future Trends. PubMed Central. 2017 PMCID: PMC5278808 PMID: 27124621 . 2. Russel Laz
Slide 14: DME is the Second-Largest Retinal Disease Market
DME is the Second-Largest Retinal Disease Market Unmet Needs: Longer-Duration Therapies AND Inflammation Control Insert not drawn to scale, for illustrative purposes only. 1. Kuo BL et al. Ophthalmol Retina. 2024;8:1074–1082. 2. Rose MA et al. Clin Exp Ophthalmol. 2020;48(9):1286–1298. 3. Bressler N
Slide 15: DME is a Multifactorial Disease Driven by VEGF and Inflammation
DME is a Multifactorial Disease Driven by VEGF and Inflammation Recent data indicates that IL-6 plays a prominent role in DME pathogenesis Dual inhibition of VEGF and IL-6 is critical for alleviating vascular leakage and inflammation in retinal vascular disease VEGF suppression is not the entire sto
Slide 16: IL-6 Signaling Occurs via Activation of the JAK Kinases
IL-6 Signaling Occurs via Activation of the JAK Kinases - Especially JAK1 1. Yang JY et al. Int J Mol Sci. 2023;24(5):4676. 2. Tanaka T, et al. Cold Spring Harb Perspect Biol. 2014;6(10):a016295. 3. Hallak JA, et al. JAMA Ophthalmol. 2024;142(8):750-758. AMD, age-related macular degeneration; DME, d
Slide 17: Vorolanib provides multi-MOA functionality by inhibiting both VEGF and IL-6
DURAVYU for DME: Vorolanib provides multi-MOA functionality by inhibiting both VEGF and IL-6 activation of inflammation Kinome tree created using AssayQuant Kinome Tree Mapping Application [online]. IL-6, interleukin 6; JAK, janus kinase; MoA, mechanism of action; PDGFR, platelet-derived growth fact
Slide 18: Single DURAVYU 2.7mg Treatment Demonstrated Meaningful Vision and Anatomical Improvement
DURAVYU in DME: Single DURAVYU 2.7mg Treatment Demonstrated Meaningful Vision and Anatomical Improvement as Early as Week 4 BCVA, best-corrected visual acuity; CST, central subfield thickness; ETDRS, Early Treatment Diabetic Retinopathy Study;. VERONA Clinicaltrials.gov Identifier: NCT06099184. Data
Slide 19: DURAVYU 2.7 mg in Supplement-Free Eyes Achieved Similar BCVA vs Anti-VEGF + Anti-IL-6
BCVA: VERONA results superimposed on BARDENAS Phase 2 Trial of anti-IL6 (vamikibart) DURAVYU in DME: 2.7 mg in Supplement-Free Eyes Achieved Similar BCVA Contrasted to Anti-VEGF + Anti-IL-6 Dosed Monthly BARDENAS Phase 2 clinical trial results adapted from Roche’s Pharma Day presentation, September
Slide 20: Dose-Dependent Reduction in Macular Leakage Area with a Single DURAVYU Injection
DURAVYU in DME: Dose-Dependent Reduction in Macular Leakage Area with a Single DURAVYU Injection aChange from baseline in vascular leakage (mm2) in the macula and in the total retinal area. Full analysis set. DME, diabetic macular edema. VERONA Clinicaltrials.gov Identifier: NCT06099184. Data on fil
Slide 21: Continued Drying with Improved BCVA After a Single DURAVYU 2.7 mg Dose
DURAVYU in DME: Continued Drying at Week 24 with Improved BCVA After a Single DURAVYU 2.7 mg Dose and No Supplementation Patient responded more favorably to DURAVYU than VABYSMO BCVA, best-corrected visual acuity; CST, central subfield thickness; D, day; VA, visual acuity; VEGF, vascular endothelial
Slide 22: Phase 3 Pivotal Plans for DME
DURAVYU for DME Phase 3 PIVOTAL Plans
Slide 23: Phase 3 Clinical Program is Designed to Drive Global Regulatory and Commercial Success
DURAVYU in DME: Phase 3 Clinical Program is Designed to Drive Global Regulatory and Commercial Success Demonstrate DURAVYU administered every six months achieves similar visual outcomes to on-label aflibercept while reducing treatment burden Two pivotal, non-inferiority trials ~240 patients per tria
Slide 24: Identical Phase 3 DME Pivotal Trials to Evaluate Non-inferiority of DURAVYU
DURAVYU in DME: Identical Phase 3 DME Pivotal Trials to Evaluate Non-inferiority of DURAVYU vs On-label Aflibercept Control Informed by positive Phase 2 VERONA trial Written alignment with the FDA; established regulatory path Leverages existing clinical trial infrastructure from LUGANO/LUCIA High ph
Slide 25: Phase 3 Pivotal Trials: Designed to Evaluate Non-Inferiority vs On-Label Aflibercept
DURAVYU in DME: Phase 3 Pivotal Trials: Designed to Evaluate Non-Inferiority of DURAVYU vs On-Label Aflibercept Control D1 W4 W8 W12 W16a W20 W24 W28 W32 W36 W40 W44 W48 W52 W56 W60 to W68 W72 W76 to W84 W88 EOS Primary endpoint Average of W52 & W56 DURAVYU 2.7 mg Aflibercept 2 mg DURAVYU dosing DUR
Slide 26: DURAVYU: The Only TKI in Development for DME
DURAVYU™: The Only TKI in Development for DME Dual anti-VEGF and anti-IL-6 inhibition alleviates both vascular leakage and inflammation in retinal vascular disease Vorolanib features a novel, multi-MOA inhibition of both VEGF and IL-6, enabling a potential synergistic approach to treating DME Positi
Slide 27: Investor Presentation October 2025
Investor Presentation October 2025
EyePoint Pharmaceuticals — Investor Presentation (October 2025) on 6ix